GlassScriptPhysician profile
Neel J Patel
NPI 1003297458
$2,762.58
in general payments reported to CMS, 2019-2025
14 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.12 · 2020: $150 · 2022: $1,222 · 2023: $451 · 2024: $635 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905 · Travel and Lodging: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.70 |
| Travel and Lodging | $458.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $891.14 | 2022 | |
| Biosense Webster, INC. | $509.79 | 2022-2025 | Carto 3 |
| Stryker Corporation | $397.46 | 2024 | Scopis Ent |
| Boston Scientific Corporation | $387.71 | 2020-2023 | Watchman, Watchman Access System |
| Recor Medical INC | $143.29 | 2025 | Paradise Ultrasound Renal Denervation System |
| Genzyme Corporation | $124.67 | 2022 | |
| Johnson & Johnson Health Care Systems INC. | $71.03 | 2022 | |
| Merck Sharp & Dohme LLC | $51.87 | 2024-2025 | Bridion |
| Atricure, INC. | $49.62 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Abiomed | $39.77 | 2025 | |
| Pfizer INC. | $34.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.90 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.57 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neel Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.